Medicare ASP Reporting: CMS Weighing Guidance, Beefed Up Internal Controls To Ensure Accuracy
Executive Summary
US Health and Human Services Department Inspector General issues two reports on manufacturer-reported average sales prices and how their accuracy could be improved. ASPs serve as the basis for Medicare Part B reimbursement and will also be used to guide implementation of price inflation-based rebate penalties for Part B drugs beginning in the first quarter of 2023.
You may also be interested in...
US Medicare Wastage ‘Refund’ Collections Delayed To ‘Align’ With IRA
A new Medicare rebate for discarded portions of single-use vials is taking effect as scheduled in January – but the first invoices won’t be issued in the fall as planned. CMS says it wants to wait to ‘align’ the collections process with the new inflation rebates enacted by the IRA.
Medicare Part D Price Inflation Rebates Won’t Mean As Much In Inflationary Times
Fewer rebate penalties than lawmakers expected may be assessed in the coming year because of the current high rate of general inflation.
The Fifth Element? A New Look At The CMS ‘Four-Part Test’
Given the US government’s continued interest in service fees paid to PBMs, sponsors would be wise to ensure that such fees are not contingent upon the volume or value of referrals or other business.